There are multiple potential applications for circulating tumor (ct)DNA in kidney cancer. The post-nephrectomy remission, adjuvant therapy decision, and monitoring for response or progression on ...
This is a prospective study of all patients with metastatic RCC unselected for high-risk features, registered at our center between September 2023 and August 2024. Baseline clinicopathologic details ...
In RCC, a phase I study of a neoantigen-targeting personalized cancer vaccine in the adjuvant setting was successful in eliciting antigen-specific and tumor-directed immune responses. 77 These studies ...
For patients with primary localized renal cell carcinoma (RCC), especially those who aren’t good candidates for surgery, noninvasive or minimally invasive ablative treatments have emerged as important ...
Prospective evidence supports SABR as a valid option for localized RCC and suggests SABR with or without immunotherapy has promise in the metastatic setting. Challenging notions of renal cell ...
A personalized cancer vaccine targeting neoantigens in high-risk renal cell carcinoma (RCC) demonstrates promising results, with no disease recurrence in any of the nine participants over a 40.2-month ...
In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell responses, among other factors. Among treatment-naive patients with metastatic ...
In RCC with metastases after nephrectomy, cancer-specific survival was higher if cancer spread to the adrenal gland or contralateral kidney. In renal cell carcinoma (RCC), both the timing and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results